Bayer: Meet Management in London (Bayer AG) - Oct 3, 2014 - "Roniciclib (BAY 1000394) – pan-CDK Inhibitor Developed for SCLC"; "Promising Phase I clinical data"; "On average, patients with stable disease (SD) stayed on treatment for 103.5 days (4-9 cycles)"; "Disease control rates were 29% (n=9/31) for SCLC, 36% for OC (n=9/25), and 33.3% for patients harboring tumor-specific mutations (n=2/6)"; "Majority of AE’s were grade 1 or 2"
P1 data • Oncology
|